Aim high - Adjuvant interferon in melanoma (high risk): No confirmation yet that low dose interferon is of benefit von Hancock, B, Turner, L, Wheatley, K, Harrison, G, Gore, M

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration inte... von Hancock, B, Wheatley, K, Harris, S, Ives, N, Harrison, G, Horsman, J, Middleton, MR, Thatcher, N, Lorigan, P, Marsden, JR, Burrows, L, Gore, M

Mesenchymal stromal cells facilitate neutrophil-trained immunity by reprogramming hematopoietic stem cells von Ng, J, Marneth, AE, Griffith, A, Younger, D, Ghanta, S, Jiao, A, Willis, G, Han, J, Imani, J, Niu, B, Keegan, JW, Hancock, B, Guo, F, Shi, Y, Perrella, MA, Lederer, JA

Interim results of a UK NCRI randomised trial comparing involved field radiotherapy with no further treatment after 3 cycles ABVD and a negative PET scan in clinical stages IA/IIA... von Radford, J, Barrington, S, O'Doherty, M, Qian, W, Mouncey, P, Pettengell, R, Hoskin, P, Bessell, E, Coltart, R, Cunningham, D, Culligan, D, Hatton, C, Johnson, P, Kruger, A, Linch, D, Lister, T, Marcus, R, Sadullah, S, Wimperis, J, Hancock, B, Illidge, T, Collaborators, PET